Observational studyFrontiers in endocrinology2026
Preoperative risk score for malignancy in Bethesda III thyroid nodules: a multicentre retrospective study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bethesda III thyroid nodules represent a heterogeneous cytological category with an estimated malignancy risk of 13-30%, creating uncertainty in clinical decision-making. This study aimed to characterise surgically resected Bethesda III thyroid nodules in a multicentre cohort and to develop a simple preoperative risk score for malignancy prediction using routinely available variables. Methods: We performed a retrospective, observational, multicentre study across four tertiary hospitals in the Region of Murcia, Spain. Adults with Bethesda III thyroid nodules who underwent thyroidectomy between 2020 and 2025 were included. Clinical, biochemical, ultrasonographic, cytological, and histopathological variables were analysed using univariate and multivariable logistic regression. A simplified integer-based risk score was derived from the independent predictors identified in the final model. Results: Eighty-five nodules were included, with a malignancy rate of 23.5%. Three preoperative variables remained independently associated with malignancy: moderate-to-high ultrasound risk, nuclear atypia on fine-needle aspiration, and lymphocytic thyroiditis on fine-needle aspiration. These predictors were incorporated into a practical score ranging from 0 to 15 points. The model showed acceptable apparent discrimination and calibration, although internal bootstrap validation indicated that cautious interpretation is required because of the limited sample size. A cut-off of 10 points or higher provided the best overall diagnostic performance, and the predicted probability of malignancy ranged from 2.4% to 74.8% across the score spectrum. Discussion: In this multicentre cohort of surgically resected Bethesda III thyroid nodules, a simple three-item exploratory score showed promising performance for preoperative malignancy risk stratification. This tool may help support clinical decision-making using variables available in routine practice, although external validation in larger independent cohorts is required before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.